optomap imaging takes less than half a second... to uncover critical information
optomap ultra-widefield imaging is a proven tool for effective clinical decision making.More than 400 published and ongoing clinical trials, as well as thousands of case studies and testimonials, show the long-term value of optomap imaging in diagnosis, treatment planning, and patient engagement
The non-mydriatic, ultra-widefield optomap technology delivers detailed 200° images in less than half a second.
optomap is a proven tool for effective clinical decision making.
optomap color images altered management in 19%, optomapfaan additional 13% (6 of 43), combined color and optomap fa altered management in a total of 48% (21 of 43 patients) overall. Disease activity was detected in 63% (27 of 43) patients when using ultra-widefield imaging when compared with 51% (22 of 43) based on examination and simulated conventional FA.
Focus: Diabetic Retinopathy and Disease Progression
Key Results:
Eyes with predominantly peripheral lesions (defined as outside of ETDRS 7 standard field) had a 4.7 fold increased risk of progression to proliferative diabetic retinopathy (PDR) and Eyes with predominantly peripheral lesions had a 3.2 fold risk of 2 step progression in DR.
A study published in Ophthalmology found that optomap confirmed the presence of wide-ranging AMD-like pathologic changes even in those without central sight-threatening macular disease. 67% of patients with age-related macular degeneration (AMD) had peripheral retinal changes associated with AMD.
Focus: The Evolution of UWF Imaging in Clinical Applications
Key Results:
A comprehensive review published in Retina describes how ultra-widefield is evolving to become the standard of care imaging modality for many diseases and is finding new clinical and research applications such as for screening and telemedicine.
Focus: Identifying Peripheral Changes Using UWF ICG
Key Results:
A study published in Retina finds that optomap icg was found to demonstrate high image quality, comparable in the central pole to competitive products and peripheral changes were visualized outside of 68° field of view in 69% of eyes evaluated.
Ocular screening programs which include optomap imaging have a higher rate of diabetic retinopathy detection and more effectively identify patients at high risk for progression.
On a single nonsteered image, the Optos optomap covered a significantly larger total retinal surface area, with greater image variability, than did the Heidelberg Spectralis ultra-widefield module. The Optos captured an appreciably wider view of the retina temporally and nasally.
